BNT211 already has orphan drug and fast-track ... at approximately 35%. BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA melanoma jab category, with the latter a ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...

the investigational CAR-T cell therapy BNT211, and the investigational ADC therapy BNT323/DB-1303; the nature and characterization of and timing for release of clinical data across BioNTech’s ...

The firm's analyst highlighted recent clinical trial results presented at ESMO 2023 for BioNTech's investigational therapy, BNT211, which targets Claudin-6 in advanced solid tumors. At the ...

The adjustment follows BioNTech's presentation of several updates ... such as BNT327 (PD-L1xVEGF), BNT113 (HPV16+ FixVac), BNT211 (CLDN6+ CAR-T), and BNT316 (CTLA-4). The spotlight was on BNT327 ...

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

BNT211 combines autologous CAR-T cells directed ... is consistent with the previously published data of CAR-T therapies. BioNTech has established a diversified clinical oncology pipeline including ...

The firm's analyst highlighted recent clinical trial results presented at ESMO 2023 for BioNTech's investigational therapy, BNT211, which targets Claudin-6 in advanced solid tumors. At the European ...

The adjustment follows BioNTech's presentation of several updates from its oncology ... such as BNT327 (PD-L1xVEGF), BNT113 (HPV16+ FixVac), BNT211 (CLDN6+ CAR-T), and BNT316 (CTLA-4). The spotlight ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European ...